nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—Nicotinamide salvaging—PTGS2—bone cancer	0.0312	0.0905	CbGpPWpGaD
Epoprostenol—PTGIS—Nicotinate metabolism—PTGS2—bone cancer	0.0166	0.0481	CbGpPWpGaD
Epoprostenol—P2RY12—Signal amplification—GNA11—bone cancer	0.0143	0.0416	CbGpPWpGaD
Epoprostenol—PTGIS—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.0137	0.0397	CbGpPWpGaD
Epoprostenol—PTGIS—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00964	0.028	CbGpPWpGaD
Epoprostenol—PTGIS—Eicosanoid Synthesis—PTGS2—bone cancer	0.00889	0.0258	CbGpPWpGaD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.00845	0.0245	CbGpPWpGaD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—GNA11—bone cancer	0.00823	0.0239	CbGpPWpGaD
Epoprostenol—PTGIS—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00782	0.0227	CbGpPWpGaD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00778	0.0226	CbGpPWpGaD
Epoprostenol—PTGIS—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.00744	0.0216	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00743	0.0216	CbGpPWpGaD
Epoprostenol—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.00544	0.0158	CbGpPWpGaD
Epoprostenol—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.00544	0.0158	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—RGS1—bone cancer	0.00508	0.0147	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—GRM4—bone cancer	0.00508	0.0147	CbGpPWpGaD
Epoprostenol—PTGIS—Arachidonic acid metabolism—PTGS2—bone cancer	0.00494	0.0143	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—GRM1—bone cancer	0.00487	0.0141	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00435	0.0126	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0042	0.0122	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—CYP3A4—bone cancer	0.00415	0.012	CbGpPWpGaD
Epoprostenol—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00375	0.0109	CbGpPWpGaD
Epoprostenol—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00361	0.0105	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—GSTP1—bone cancer	0.00355	0.0103	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.00335	0.00971	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.00326	0.00945	CbGpPWpGaD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.00317	0.00921	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—GNA11—bone cancer	0.00314	0.00909	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—GRM4—bone cancer	0.00308	0.00892	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00298	0.00865	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—GRM4—bone cancer	0.00283	0.00821	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—GRM4—bone cancer	0.00283	0.00821	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.0028	0.00813	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—RB1—bone cancer	0.0028	0.00812	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IL3—bone cancer	0.0027	0.00784	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—GRM1—bone cancer	0.00267	0.00773	CbGpPWpGaD
Epoprostenol—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00258	0.00747	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—NDUFA12—bone cancer	0.00249	0.00722	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00245	0.00712	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—GRM1—bone cancer	0.00245	0.00712	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—GRM1—bone cancer	0.00245	0.00712	CbGpPWpGaD
Epoprostenol—Eczema—Doxorubicin—bone cancer	0.00238	0.00364	CcSEcCtD
Epoprostenol—Hepatic failure—Doxorubicin—bone cancer	0.00238	0.00364	CcSEcCtD
Epoprostenol—Cardiac failure—Epirubicin—bone cancer	0.00237	0.00362	CcSEcCtD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—EGFR—bone cancer	0.00234	0.00679	CbGpPWpGaD
Epoprostenol—Myalgia—Cisplatin—bone cancer	0.00231	0.00353	CcSEcCtD
Epoprostenol—Anxiety—Cisplatin—bone cancer	0.0023	0.00352	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.0023	0.00351	CcSEcCtD
Epoprostenol—Anaphylactic shock—Cisplatin—bone cancer	0.00222	0.00338	CcSEcCtD
Epoprostenol—Oedema—Cisplatin—bone cancer	0.00222	0.00338	CcSEcCtD
Epoprostenol—Infection—Cisplatin—bone cancer	0.0022	0.00336	CcSEcCtD
Epoprostenol—Cardiac failure—Doxorubicin—bone cancer	0.0022	0.00335	CcSEcCtD
Epoprostenol—Nervous system disorder—Cisplatin—bone cancer	0.00217	0.00332	CcSEcCtD
Epoprostenol—Thrombocytopenia—Cisplatin—bone cancer	0.00217	0.00331	CcSEcCtD
Epoprostenol—Tachycardia—Cisplatin—bone cancer	0.00216	0.0033	CcSEcCtD
Epoprostenol—Skin disorder—Cisplatin—bone cancer	0.00215	0.00329	CcSEcCtD
Epoprostenol—Hyperhidrosis—Cisplatin—bone cancer	0.00214	0.00327	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Epirubicin—bone cancer	0.00212	0.00323	CcSEcCtD
Epoprostenol—Anorexia—Cisplatin—bone cancer	0.00211	0.00323	CcSEcCtD
Epoprostenol—Hypotension—Cisplatin—bone cancer	0.00207	0.00316	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—NT5C3A—bone cancer	0.00206	0.00598	CbGpPWpGaD
Epoprostenol—Abdominal discomfort—Methotrexate—bone cancer	0.00205	0.00313	CcSEcCtD
Epoprostenol—Gastritis—Epirubicin—bone cancer	0.00205	0.00313	CcSEcCtD
Epoprostenol—Pancytopenia—Methotrexate—bone cancer	0.00203	0.0031	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00202	0.00308	CcSEcCtD
Epoprostenol—Abdominal distension—Epirubicin—bone cancer	0.00202	0.00308	CcSEcCtD
Epoprostenol—Paraesthesia—Cisplatin—bone cancer	0.00199	0.00304	CcSEcCtD
Epoprostenol—Dyspnoea—Cisplatin—bone cancer	0.00198	0.00302	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Doxorubicin—bone cancer	0.00196	0.00299	CcSEcCtD
Epoprostenol—Decreased appetite—Cisplatin—bone cancer	0.00193	0.00294	CcSEcCtD
Epoprostenol—Pneumonia—Methotrexate—bone cancer	0.00192	0.00293	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Cisplatin—bone cancer	0.00191	0.00292	CcSEcCtD
Epoprostenol—Infestation NOS—Methotrexate—bone cancer	0.00191	0.00291	CcSEcCtD
Epoprostenol—Infestation—Methotrexate—bone cancer	0.00191	0.00291	CcSEcCtD
Epoprostenol—Depression—Methotrexate—bone cancer	0.0019	0.0029	CcSEcCtD
Epoprostenol—Pancytopenia—Epirubicin—bone cancer	0.0019	0.0029	CcSEcCtD
Epoprostenol—Gastritis—Doxorubicin—bone cancer	0.0019	0.00289	CcSEcCtD
Epoprostenol—Pain—Cisplatin—bone cancer	0.0019	0.00289	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—SMO—bone cancer	0.00188	0.00545	CbGpPWpGaD
Epoprostenol—Abdominal distension—Doxorubicin—bone cancer	0.00186	0.00285	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—bone cancer	0.00183	0.00279	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—bone cancer	0.00182	0.00278	CcSEcCtD
Epoprostenol—Weight decreased—Epirubicin—bone cancer	0.00181	0.00276	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—bone cancer	0.0018	0.00275	CcSEcCtD
Epoprostenol—Pneumonia—Epirubicin—bone cancer	0.0018	0.00274	CcSEcCtD
Epoprostenol—Infestation—Epirubicin—bone cancer	0.00178	0.00272	CcSEcCtD
Epoprostenol—Infestation NOS—Epirubicin—bone cancer	0.00178	0.00272	CcSEcCtD
Epoprostenol—Pancytopenia—Doxorubicin—bone cancer	0.00176	0.00268	CcSEcCtD
Epoprostenol—Body temperature increased—Cisplatin—bone cancer	0.00175	0.00267	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—RGS1—bone cancer	0.00174	0.00504	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—GRM4—bone cancer	0.00174	0.00504	CbGpPWpGaD
Epoprostenol—Urinary tract infection—Epirubicin—bone cancer	0.00173	0.00265	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—SMO—bone cancer	0.00173	0.00501	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—SMO—bone cancer	0.00173	0.00501	CbGpPWpGaD
Epoprostenol—Haemoglobin—Methotrexate—bone cancer	0.00172	0.00263	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—bone cancer	0.00171	0.00261	CcSEcCtD
Epoprostenol—Sweating—Epirubicin—bone cancer	0.00171	0.00261	CcSEcCtD
Epoprostenol—Haematuria—Epirubicin—bone cancer	0.0017	0.0026	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—bone cancer	0.0017	0.00259	CcSEcCtD
Epoprostenol—Epistaxis—Epirubicin—bone cancer	0.00168	0.00257	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—SPARC—bone cancer	0.00168	0.00487	CbGpPWpGaD
Epoprostenol—Weight decreased—Doxorubicin—bone cancer	0.00168	0.00256	CcSEcCtD
Epoprostenol—Sinusitis—Epirubicin—bone cancer	0.00167	0.00256	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—bone cancer	0.00166	0.00254	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—bone cancer	0.00165	0.00252	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—bone cancer	0.00165	0.00252	CcSEcCtD
Epoprostenol—Hypersensitivity—Cisplatin—bone cancer	0.00163	0.00249	CcSEcCtD
Epoprostenol—Bradycardia—Epirubicin—bone cancer	0.00163	0.00249	CcSEcCtD
Epoprostenol—Haemoglobin—Epirubicin—bone cancer	0.00161	0.00246	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—bone cancer	0.00161	0.00245	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—bone cancer	0.00161	0.00245	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—bone cancer	0.0016	0.00245	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—RGS1—bone cancer	0.0016	0.00464	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—GRM4—bone cancer	0.0016	0.00464	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—GRM4—bone cancer	0.0016	0.00464	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—RGS1—bone cancer	0.0016	0.00464	CbGpPWpGaD
Epoprostenol—Hypoaesthesia—Epirubicin—bone cancer	0.00159	0.00243	CcSEcCtD
Epoprostenol—Asthenia—Cisplatin—bone cancer	0.00159	0.00243	CcSEcCtD
Epoprostenol—Pharyngitis—Epirubicin—bone cancer	0.00159	0.00243	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—bone cancer	0.00159	0.00243	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—bone cancer	0.00158	0.00242	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—bone cancer	0.00158	0.00241	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—GRM4—bone cancer	0.00158	0.00458	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—RGS1—bone cancer	0.00158	0.00458	CbGpPWpGaD
Epoprostenol—Haematuria—Doxorubicin—bone cancer	0.00157	0.0024	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—bone cancer	0.00157	0.0024	CcSEcCtD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00156	0.00452	CbGpPWpGaD
Epoprostenol—Epistaxis—Doxorubicin—bone cancer	0.00156	0.00238	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—bone cancer	0.00155	0.00237	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—bone cancer	0.00155	0.00236	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—SPARC—bone cancer	0.00155	0.00448	CbGpPWpGaD
Epoprostenol—Mediastinal disorder—Methotrexate—bone cancer	0.00154	0.00236	CcSEcCtD
Epoprostenol—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00154	0.00446	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—GNA11—bone cancer	0.00154	0.00446	CbGpPWpGaD
Epoprostenol—Chills—Methotrexate—bone cancer	0.00154	0.00234	CcSEcCtD
Epoprostenol—Diarrhoea—Cisplatin—bone cancer	0.00152	0.00231	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—bone cancer	0.00151	0.0023	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—GRM1—bone cancer	0.00151	0.00437	CbGpPWpGaD
Epoprostenol—Mental disorder—Methotrexate—bone cancer	0.0015	0.00229	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—bone cancer	0.00149	0.00227	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—bone cancer	0.00149	0.00227	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—bone cancer	0.00149	0.00227	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—bone cancer	0.00149	0.00227	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—bone cancer	0.00148	0.00226	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—bone cancer	0.00148	0.00225	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—bone cancer	0.00147	0.00225	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—bone cancer	0.00146	0.00223	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—bone cancer	0.00146	0.00222	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—bone cancer	0.00145	0.00222	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—GRM4—bone cancer	0.00145	0.00421	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—GRM4—bone cancer	0.00145	0.00421	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—RGS1—bone cancer	0.00145	0.00421	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—RGS1—bone cancer	0.00145	0.00421	CbGpPWpGaD
Epoprostenol—Mediastinal disorder—Epirubicin—bone cancer	0.00144	0.0022	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—bone cancer	0.00144	0.0022	CcSEcCtD
Epoprostenol—Chills—Epirubicin—bone cancer	0.00144	0.00219	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—GNA11—bone cancer	0.00141	0.0041	CbGpPWpGaD
Epoprostenol—Vomiting—Cisplatin—bone cancer	0.00141	0.00215	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—bone cancer	0.0014	0.00214	CcSEcCtD
Epoprostenol—Rash—Cisplatin—bone cancer	0.0014	0.00213	CcSEcCtD
Epoprostenol—Dermatitis—Cisplatin—bone cancer	0.0014	0.00213	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—IL3—bone cancer	0.00139	0.00404	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—GRM1—bone cancer	0.00139	0.00402	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—GRM1—bone cancer	0.00139	0.00402	CbGpPWpGaD
Epoprostenol—Anaemia—Methotrexate—bone cancer	0.00138	0.0021	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—bone cancer	0.00138	0.0021	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—bone cancer	0.00138	0.0021	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—bone cancer	0.00137	0.0021	CcSEcCtD
Epoprostenol—Tension—Epirubicin—bone cancer	0.00137	0.00209	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—GRM1—bone cancer	0.00137	0.00397	CbGpPWpGaD
Epoprostenol—Nervousness—Epirubicin—bone cancer	0.00135	0.00207	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—bone cancer	0.00135	0.00206	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—bone cancer	0.00135	0.00205	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—bone cancer	0.00134	0.00205	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—bone cancer	0.00134	0.00204	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—bone cancer	0.00133	0.00203	CcSEcCtD
Epoprostenol—Nausea—Cisplatin—bone cancer	0.00132	0.00201	CcSEcCtD
Epoprostenol—Cough—Methotrexate—bone cancer	0.0013	0.00199	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—bone cancer	0.0013	0.00198	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—bone cancer	0.00129	0.00197	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—IL3—bone cancer	0.00128	0.00372	CbGpPWpGaD
Epoprostenol—Agitation—Epirubicin—bone cancer	0.00128	0.00196	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—bone cancer	0.00127	0.00194	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—bone cancer	0.00127	0.00194	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—bone cancer	0.00127	0.00194	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—bone cancer	0.00127	0.00194	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—bone cancer	0.00127	0.00193	CcSEcCtD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00126	0.00366	CbGpPWpGaD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00126	0.00192	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—GRM1—bone cancer	0.00126	0.00365	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—GRM1—bone cancer	0.00126	0.00365	CbGpPWpGaD
Epoprostenol—Nervousness—Doxorubicin—bone cancer	0.00125	0.00191	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—bone cancer	0.00125	0.00191	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—bone cancer	0.00125	0.00191	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—bone cancer	0.00124	0.00189	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—bone cancer	0.00123	0.00188	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—bone cancer	0.00123	0.00187	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—bone cancer	0.00123	0.00187	CcSEcCtD
Epoprostenol—Cough—Epirubicin—bone cancer	0.00122	0.00186	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—bone cancer	0.00122	0.00186	CcSEcCtD
Epoprostenol—Infection—Methotrexate—bone cancer	0.00121	0.00184	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—bone cancer	0.00119	0.00182	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—bone cancer	0.00119	0.00182	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—bone cancer	0.00119	0.00182	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—bone cancer	0.00119	0.00181	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—bone cancer	0.00119	0.00181	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—bone cancer	0.00119	0.00181	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—bone cancer	0.00119	0.00181	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—bone cancer	0.00118	0.00181	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—bone cancer	0.00118	0.0018	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00118	0.0018	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—bone cancer	0.00118	0.00179	CcSEcCtD
Epoprostenol—Dry mouth—Epirubicin—bone cancer	0.00116	0.00177	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—bone cancer	0.00116	0.00177	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—bone cancer	0.00116	0.00177	CcSEcCtD
Epoprostenol—Confusional state—Epirubicin—bone cancer	0.00115	0.00175	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—bone cancer	0.00114	0.00174	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—bone cancer	0.00114	0.00174	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—bone cancer	0.00114	0.00174	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—bone cancer	0.00114	0.00173	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—bone cancer	0.00113	0.00173	CcSEcCtD
Epoprostenol—Infection—Epirubicin—bone cancer	0.00113	0.00173	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—bone cancer	0.00113	0.00172	CcSEcCtD
Epoprostenol—Shock—Epirubicin—bone cancer	0.00112	0.00171	CcSEcCtD
Epoprostenol—Nervous system disorder—Epirubicin—bone cancer	0.00112	0.0017	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—bone cancer	0.00111	0.0017	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—bone cancer	0.00111	0.0017	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00111	0.00169	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—bone cancer	0.00111	0.00169	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—bone cancer	0.0011	0.00168	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—bone cancer	0.0011	0.00168	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—bone cancer	0.0011	0.00168	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—bone cancer	0.0011	0.00168	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—bone cancer	0.0011	0.00168	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—bone cancer	0.00109	0.00167	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—bone cancer	0.00109	0.00167	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00109	0.00167	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—bone cancer	0.00109	0.00166	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—bone cancer	0.00108	0.00166	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—bone cancer	0.00108	0.00165	CcSEcCtD
Epoprostenol—PTGIS—Disease—ENO2—bone cancer	0.00108	0.00313	CbGpPWpGaD
Epoprostenol—Dry mouth—Doxorubicin—bone cancer	0.00107	0.00164	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—bone cancer	0.00107	0.00163	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—bone cancer	0.00106	0.00162	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—bone cancer	0.00106	0.00162	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—bone cancer	0.00106	0.00161	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—bone cancer	0.00105	0.00161	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—bone cancer	0.00105	0.00161	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—bone cancer	0.00105	0.0016	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—bone cancer	0.00105	0.0016	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—bone cancer	0.00105	0.0016	CcSEcCtD
Epoprostenol—Pain—Methotrexate—bone cancer	0.00104	0.00159	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00104	0.00158	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—bone cancer	0.00104	0.00158	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—bone cancer	0.00103	0.00158	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—bone cancer	0.00103	0.00157	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—bone cancer	0.00103	0.00157	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—bone cancer	0.00103	0.00157	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—bone cancer	0.00102	0.00156	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—bone cancer	0.00102	0.00156	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—bone cancer	0.00102	0.00155	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—bone cancer	0.00101	0.00155	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—bone cancer	0.00101	0.00154	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—bone cancer	0.001	0.00153	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—bone cancer	0.001	0.00153	CcSEcCtD
Epoprostenol—PTGIS—Disease—DHFR—bone cancer	0.001	0.0029	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Methotrexate—bone cancer	0.000995	0.00152	CcSEcCtD
Epoprostenol—Decreased appetite—Epirubicin—bone cancer	0.00099	0.00151	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—bone cancer	0.000984	0.0015	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—bone cancer	0.000983	0.0015	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—bone cancer	0.000981	0.0015	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—bone cancer	0.000973	0.00149	CcSEcCtD
Epoprostenol—Pain—Epirubicin—bone cancer	0.000973	0.00149	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—GNA11—bone cancer	0.000971	0.00282	CbGpPWpGaD
Epoprostenol—Urticaria—Methotrexate—bone cancer	0.000966	0.00147	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—SMO—bone cancer	0.000964	0.0028	CbGpPWpGaD
Epoprostenol—Body temperature increased—Methotrexate—bone cancer	0.000962	0.00147	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—bone cancer	0.000962	0.00147	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00096	0.00146	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—bone cancer	0.000953	0.00145	CcSEcCtD
Epoprostenol—Paraesthesia—Doxorubicin—bone cancer	0.000946	0.00144	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—bone cancer	0.000939	0.00143	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—bone cancer	0.000936	0.00143	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—RGS1—bone cancer	0.000932	0.0027	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GRM4—bone cancer	0.000932	0.0027	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Epirubicin—bone cancer	0.000931	0.00142	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—bone cancer	0.000927	0.00142	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—bone cancer	0.000916	0.0014	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—PLAU—bone cancer	0.000914	0.00265	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000909	0.00139	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—bone cancer	0.000908	0.00139	CcSEcCtD
Epoprostenol—Urticaria—Epirubicin—bone cancer	0.000904	0.00138	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—ENO2—bone cancer	0.000903	0.00262	CbGpPWpGaD
Epoprostenol—Pain—Doxorubicin—bone cancer	0.000901	0.00137	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—bone cancer	0.000901	0.00137	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—bone cancer	0.0009	0.00137	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—bone cancer	0.0009	0.00137	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—bone cancer	0.000896	0.00137	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—GNA11—bone cancer	0.000894	0.00259	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—GNA11—bone cancer	0.000894	0.00259	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—SMO—bone cancer	0.000887	0.00257	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—SMO—bone cancer	0.000887	0.00257	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—GNA11—bone cancer	0.000882	0.00256	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL3—bone cancer	0.00088	0.00255	CbGpPWpGaD
Epoprostenol—Asthenia—Methotrexate—bone cancer	0.000873	0.00133	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Doxorubicin—bone cancer	0.000861	0.00131	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—bone cancer	0.000861	0.00131	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—GRM4—bone cancer	0.000858	0.00249	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RGS1—bone cancer	0.000858	0.00249	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RGS1—bone cancer	0.000858	0.00249	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GRM4—bone cancer	0.000858	0.00249	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PLAU—bone cancer	0.000841	0.00244	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Epirubicin—bone cancer	0.000839	0.00128	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—DHFR—bone cancer	0.000838	0.00243	CbGpPWpGaD
Epoprostenol—Urticaria—Doxorubicin—bone cancer	0.000837	0.00128	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—bone cancer	0.000833	0.00127	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—bone cancer	0.000833	0.00127	CcSEcCtD
Epoprostenol—Diarrhoea—Methotrexate—bone cancer	0.000832	0.00127	CcSEcCtD
Epoprostenol—Asthenia—Epirubicin—bone cancer	0.000817	0.00125	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—GNA11—bone cancer	0.000812	0.00235	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—GNA11—bone cancer	0.000812	0.00235	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL3—bone cancer	0.00081	0.00235	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL3—bone cancer	0.00081	0.00235	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GRM1—bone cancer	0.000808	0.00234	CbGpPWpGaD
Epoprostenol—Pruritus—Epirubicin—bone cancer	0.000805	0.00123	CcSEcCtD
Epoprostenol—Dizziness—Methotrexate—bone cancer	0.000804	0.00123	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—IL3—bone cancer	0.000799	0.00232	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000799	0.00232	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000799	0.00232	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GNA11—bone cancer	0.000783	0.00227	CbGpPWpGaD
Epoprostenol—Diarrhoea—Epirubicin—bone cancer	0.000779	0.00119	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—bone cancer	0.000776	0.00118	CcSEcCtD
Epoprostenol—Vomiting—Methotrexate—bone cancer	0.000773	0.00118	CcSEcCtD
Epoprostenol—Rash—Methotrexate—bone cancer	0.000767	0.00117	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—bone cancer	0.000766	0.00117	CcSEcCtD
Epoprostenol—Headache—Methotrexate—bone cancer	0.000762	0.00116	CcSEcCtD
Epoprostenol—Asthenia—Doxorubicin—bone cancer	0.000756	0.00115	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—bone cancer	0.000753	0.00115	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—bone cancer	0.000745	0.00114	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—GRM1—bone cancer	0.000744	0.00216	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GRM1—bone cancer	0.000744	0.00216	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL3—bone cancer	0.000736	0.00213	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL3—bone cancer	0.000736	0.00213	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFBR2—bone cancer	0.000725	0.0021	CbGpPWpGaD
Epoprostenol—Vomiting—Epirubicin—bone cancer	0.000724	0.0011	CcSEcCtD
Epoprostenol—Nausea—Methotrexate—bone cancer	0.000723	0.0011	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—bone cancer	0.000721	0.0011	CcSEcCtD
Epoprostenol—Rash—Epirubicin—bone cancer	0.000718	0.0011	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—bone cancer	0.000717	0.00109	CcSEcCtD
Epoprostenol—Headache—Epirubicin—bone cancer	0.000713	0.00109	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CYP3A4—bone cancer	0.00071	0.00206	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000707	0.00205	CbGpPWpGaD
Epoprostenol—Dizziness—Doxorubicin—bone cancer	0.000697	0.00106	CcSEcCtD
Epoprostenol—Nausea—Epirubicin—bone cancer	0.000676	0.00103	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000671	0.00195	CbGpPWpGaD
Epoprostenol—Vomiting—Doxorubicin—bone cancer	0.00067	0.00102	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—bone cancer	0.000664	0.00101	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—bone cancer	0.000664	0.00101	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000662	0.00192	CbGpPWpGaD
Epoprostenol—Headache—Doxorubicin—bone cancer	0.00066	0.00101	CcSEcCtD
Epoprostenol—Nausea—Doxorubicin—bone cancer	0.000626	0.000955	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—GSTP1—bone cancer	0.000607	0.00176	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000574	0.00166	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SMO—bone cancer	0.00057	0.00165	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000566	0.00164	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SMO—bone cancer	0.000524	0.00152	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SMO—bone cancer	0.000524	0.00152	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GNA11—bone cancer	0.000521	0.00151	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KIT—bone cancer	0.000495	0.00144	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ATF1—bone cancer	0.000484	0.0014	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GNA11—bone cancer	0.000479	0.00139	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GNA11—bone cancer	0.000479	0.00139	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL3—bone cancer	0.000472	0.00137	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—BRAF—bone cancer	0.000465	0.00135	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ATF1—bone cancer	0.000446	0.00129	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ATF1—bone cancer	0.000446	0.00129	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL3—bone cancer	0.000435	0.00126	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL3—bone cancer	0.000435	0.00126	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFBR2—bone cancer	0.000404	0.00117	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000402	0.00117	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MDM2—bone cancer	0.00039	0.00113	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1R—bone cancer	0.00038	0.0011	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—bone cancer	0.000376	0.00109	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFBR2—bone cancer	0.000372	0.00108	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFBR2—bone cancer	0.000372	0.00108	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—bone cancer	0.000367	0.00107	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1R—bone cancer	0.00035	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1R—bone cancer	0.00035	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—bone cancer	0.000338	0.00098	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NT5C3A—bone cancer	0.000333	0.000967	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—bone cancer	0.000315	0.000913	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KIT—bone cancer	0.000276	0.000799	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—bone cancer	0.000266	0.000772	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BRAF—bone cancer	0.000259	0.000751	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KIT—bone cancer	0.000254	0.000736	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KIT—bone cancer	0.000254	0.000736	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—bone cancer	0.000251	0.000728	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BRAF—bone cancer	0.000238	0.000691	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BRAF—bone cancer	0.000238	0.000691	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—bone cancer	0.000231	0.00067	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—bone cancer	0.000231	0.00067	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MDM2—bone cancer	0.000217	0.00063	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MDM2—bone cancer	0.0002	0.000579	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MDM2—bone cancer	0.0002	0.000579	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JUN—bone cancer	0.000189	0.000547	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—bone cancer	0.000184	0.000532	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JUN—bone cancer	0.000174	0.000504	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JUN—bone cancer	0.000174	0.000504	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—bone cancer	0.000169	0.00049	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—bone cancer	0.000169	0.00049	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—bone cancer	0.000148	0.00043	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ENO2—bone cancer	0.000146	0.000423	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—bone cancer	0.000137	0.000396	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—bone cancer	0.000137	0.000396	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—DHFR—bone cancer	0.000135	0.000393	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GNA11—bone cancer	0.000127	0.000367	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—bone cancer	0.000125	0.000361	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP3A4—bone cancer	0.000115	0.000333	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—bone cancer	0.000115	0.000332	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—bone cancer	0.000115	0.000332	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000114	0.000331	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—bone cancer	9.81e-05	0.000285	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—bone cancer	5.08e-05	0.000147	CbGpPWpGaD
